Aldara gets FDA nod for treatment of sBCC

Article

St. Paul, Minn. - Aldara (imiquimod) Cream 5 percent, a topical immune response modifier, has received U.S. Food and Drug Administration (FDA) approval for the treatment of superficial basal cell carcinoma (sBCC).

Related Videos
Related Content

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023

Derm In The News: September 24-30

September 30th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

The Importance of Timing With Live Vaccinations in Pediatric Atopic Dermatitis

September 30th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Discovering Dermatology Times: September 2023 BCC Management Supplement

September 29th 2023

Understanding Eyebrow and Eyelash Hair Loss in Severe Alopecia Areata

September 29th 2023
© 2023 MJH Life Sciences

All rights reserved.